190 related articles for article (PubMed ID: 36845155)
1. Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Lofek S; Wyss T; Melero I; de Vries IJM; Harari A; Romero P; Kandalaft LE; Viganó S
Front Immunol; 2023; 14():1119371. PubMed ID: 36845155
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Wyss T; Inoges S; de Vries IJM; Dartiguenave F; Jichlinski P; Derrè L; Coukos G; Melero I; Harari A; Romero P; Viganó S; Kandalaft LE
Eur J Cancer; 2020 Aug; 135():173-182. PubMed ID: 32590296
[TBL] [Abstract][Full Text] [Related]
3. Interaction of Type 1 Porcine Reproductive and Respiratory Syndrome Virus With
Li Y; Mateu E
Front Immunol; 2021; 12():674185. PubMed ID: 34177915
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
5. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
6. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
7. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
8. Human CD141
Minoda Y; Virshup I; Leal Rojas I; Haigh O; Wong Y; Miles JJ; Wells CA; Radford KJ
Front Immunol; 2017; 8():1419. PubMed ID: 29163495
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy analysis of Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with Paclitaxel-Cisplatin Chemotherapy in patients with Advanced Ovarian Cancer.
Gao Y; Hao Y; Jia Y
J BUON; 2021; 26(2):553-560. PubMed ID: 34077005
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.
Baek S; Kim YM; Kim SB; Kim CS; Kwon SW; Kim Y; Kim H; Lee H
Cell Mol Immunol; 2015 Jan; 12(1):87-95. PubMed ID: 24976269
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
Chu CS; Boyer J; Schullery DS; Gimotty PA; Gamerman V; Bender J; Levine BL; Coukos G; Rubin SC; Morgan MA; Vonderheide RH; June CH
Cancer Immunol Immunother; 2012 May; 61(5):629-41. PubMed ID: 22021066
[TBL] [Abstract][Full Text] [Related]
12. Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.
Carenza C; Calcaterra F; Oriolo F; Di Vito C; Ubezio M; Della Porta MG; Mavilio D; Della Bella S
Front Immunol; 2019; 10():1325. PubMed ID: 31244860
[TBL] [Abstract][Full Text] [Related]
13. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
Huber A; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2804. PubMed ID: 30559743
[TBL] [Abstract][Full Text] [Related]
14. The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
Kobayashi M; Chiba A; Izawa H; Yanagida E; Okamoto M; Shimodaira S; Yonemitsu Y; Shibamoto Y; Suzuki N; Nagaya M;
J Ovarian Res; 2014 May; 7():48. PubMed ID: 25298213
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
[TBL] [Abstract][Full Text] [Related]
16. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
17. Precise Delineation and Transcriptional Characterization of Bovine Blood Dendritic-Cell and Monocyte Subsets.
Talker SC; Baumann A; Barut GT; Keller I; Bruggmann R; Summerfield A
Front Immunol; 2018; 9():2505. PubMed ID: 30425716
[TBL] [Abstract][Full Text] [Related]
18. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
19. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
20. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
